AOD-9604 Interactions: Alcohol, Caffeine, Food & Other Compounds in the Literature

AOD-9604 is a synthetic peptide corresponding to a C-terminal region of human growth hormone that was investigated for effects on lipid metabolism. Questions about combining it with alcohol, caffeine, meals or other compounds are common, but the published record on this peptide is narrow. The verified literature summarised here consists of animal pharmacology and obesity-drug reviews, and none of those papers examined co-administration with alcohol, caffeine, or a defined feeding or fasting schedule. This page states that plainly and then describes the mechanistic reasoning researchers apply when direct interaction data are absent, labelled as reasoning rather than as findings.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any compound, combination or health decision.

What the Verified Literature Actually Examined

The core preclinical paper evaluated human growth hormone and its lipolytic fragment, AOD9604, on lipid metabolism following chronic treatment in obese mice and in beta(3)-adrenergic receptor knock-out mice (PMID 11713213). The study was designed around the question of whether the fragment's effects on fat metabolism depended on the beta(3)-adrenergic receptor, which is why a knock-out model was included alongside obese animals (PMID 11713213). That design addressed receptor-pathway dependence, not dietary context, not ethanol, and not stimulants.

Two secondary sources placed the compound in a development pipeline rather than reporting new experiments. A "Gateways to clinical trials" compilation catalogued compounds moving through clinical development, listing agents by name and stage (PMID 14571286). A Polish-language review of currently used antiobesity drugs and new compounds in clinical development surveyed the obesity pharmacotherapy landscape of its period (PMID 17971763). Neither review was an interaction study, and neither reported co-administration data for alcohol, caffeine or food.

Summary of the citation set: across the chronic-treatment mouse work on the lipolytic growth hormone fragment (PMID 11713213) and the two development-stage reviews (PMID 14571286, PMID 17971763), no passage described an interaction arm, a beverage, a stimulant or a feeding protocol as a study variable.

AOD-9604 and Alcohol: No Interaction Study Exists

There is no published trial, animal study or case report in the verified set that administered AOD-9604 together with ethanol. The mouse study that examined the fragment during chronic treatment in obese and beta(3)-AR knock-out animals did not include an alcohol arm (PMID 11713213), and the two reviews did not report any such experiment (PMID 14571286, PMID 17971763). Anything stated about this pairing is therefore inference, not evidence.

The mechanistic reasoning researchers use (labelled as reasoning, not findings)

When no interaction data exist, pharmacologists typically reason from three separate questions. The first is whether the two agents share a metabolic route. Peptides of this size are generally handled by peptidase-mediated breakdown rather than by the hepatic cytochrome P450 enzymes that dominate small-molecule interactions with ethanol, so the classical "enzyme competition" interaction framework is usually considered a poor fit for peptides. That is a general pharmacology principle, not a finding reported in any of the cited papers.

The second question is whether the agents act on the same downstream physiology. Because the preclinical interest in this fragment concerned lipid metabolism (PMID 11713213), and because ethanol is independently known in general physiology to alter hepatic lipid handling and substrate oxidation, researchers would frame any hypothetical overlap as a shared-endpoint question rather than a direct chemical interaction. No study in the verified set tested that hypothesis.

The third question is confounding in measurement: if a study measured body composition or lipid endpoints, alcohol intake would be treated as a variable to control or record, because it contributes energy and affects the same readouts. The chronic-treatment mouse experiments were conducted in controlled animal housing, which removes that confounder by design rather than by testing it (PMID 11713213).

AOD-9604 and Caffeine or Other Stimulants

No verified paper co-administered caffeine, ephedrine, yohimbine or any other stimulant with AOD-9604. The reason this question recurs is mechanistic: stimulants are commonly discussed in terms of adrenergic signalling, and the central preclinical question about this fragment was precisely whether its effect on fat metabolism required the beta(3)-adrenergic receptor, which is why beta(3)-AR knock-out mice were used (PMID 11713213).

Researchers describe that design logic as follows: if an effect persists in animals lacking a receptor, the receptor is not required for that effect; if it disappears, the pathway is implicated. The knock-out comparison in that study was the tool used to interrogate beta(3)-AR dependence during chronic treatment (PMID 11713213). What the study did not do was add an adrenergic stimulant on top of the peptide to see whether effects were additive, synergistic or offsetting, that experiment is simply absent from the record, as is any mention of it in the development-stage reviews (PMID 14571286, PMID 17971763).

Food, Fasting and Meal Timing

No published study in the verified set compared AOD-9604 administration in fed versus fasted states, or examined whether macronutrient composition altered its measured effects. The mouse work described chronic treatment in obese animals and in beta(3)-AR knock-out animals (PMID 11713213); diet-as-interaction was not the reported variable.

The mechanistic reasoning researchers cite for why feeding state is raised at all is general metabolic physiology: insulin, free fatty acid availability and substrate oxidation shift substantially between fed and fasted states, so any endpoint touching lipid metabolism can be sensitive to when a measurement is taken. That is why nutrition-controlled protocols are standard in metabolic research. It is a design principle, not a reported interaction for this peptide.

Other Compounds Readers Ask About

Human growth hormone

The closest thing to a compound comparison in the verified record is the mouse study, which evaluated human GH alongside its lipolytic fragment on lipid metabolism following chronic treatment (PMID 11713213). That was a parallel evaluation of two agents, not a combination experiment, and the distinction matters: comparing A and B separately says nothing about what A plus B does.

Antiobesity pharmacotherapy

A review of currently used antiobesity drugs and new compounds in clinical development described the field as it stood, grouping approved agents and investigational candidates (PMID 17971763). A separate clinical-trials gateway compilation tracked compounds through development stages (PMID 14571286). Being listed in the same review as another agent is a cataloguing fact, not evidence that the two were studied together or that their effects combine in any particular way.

Other peptides

No verified paper examined AOD-9604 alongside other research peptides. Claims about peptide "stacks" do not derive from the papers cited on this page (PMID 11713213, PMID 14571286, PMID 17971763).

Interactions and Adverse Events: What Studies Report

The verified citation set does not contain an interaction-related adverse event report for AOD-9604. The chronic-treatment animal study was framed around lipid-metabolism outcomes in obese and beta(3)-AR knock-out mice rather than around a tolerability comparison against alcohol, caffeine or food (PMID 11713213). The development-stage reviews catalogued compounds rather than pooling safety signals for this peptide specifically (PMID 14571286, PMID 17971763).

Absence of a reported adverse interaction in a small literature is not the same as evidence that no interaction occurs. Researchers describe this as the distinction between negative evidence (a study looked and found nothing) and no evidence (no study looked). For every interaction question on this page, the situation is the latter.

How to Read Interaction Claims About This Peptide

• Check whether a combination was actually administered. Comparative studies that run two agents in separate groups, as with human GH and its fragment in the mouse work (PMID 11713213), do not generate combination data.
• Distinguish reviews from experiments. Pipeline compilations list compounds and stages (PMID 14571286) and obesity-drug reviews survey a field (PMID 17971763); neither generates new interaction data.
• Watch for species and model limits. Findings obtained in obese mice and beta(3)-AR knock-out mice describe those models (PMID 11713213).
• Treat mechanism as hypothesis. Reasoning from receptor pathways or metabolic routes generates testable predictions, not results.

Readers looking for background on what the peptide is and what the primary literature reported overall can see the companion overview at /learn/aod-9604/.

Regulatory Context

AOD-9604 is not an approved drug product in the United States; it appeared in the literature as an investigational candidate catalogued among compounds in clinical development (PMID 14571286) and in a review of antiobesity drugs and compounds then in development (PMID 17971763). Material sold under this name is typically labelled for research use only. This page describes published literature and regulatory status and is not legal or medical advice.

References

• The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice (Endocrinology, 2001)
• Gateways to clinical trials (Methods and Findings in Experimental and Clinical Pharmacology, 2003)
• [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development] (Postepy Higieny i Medycyny Doswiadczalnej (Online), 2007)